Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
46 Leser
Artikel bewerten:
(0)

inVentiv Health Continues its inVentiv Pharma Forum Series with June 21 Program for Pharmaceutical Sales and Marketing Professionals


SOMERSET, N.J., June 13 /PRNewswire-FirstCall/ -- inVentiv Health, Inc. announced today that it will host a conference focused on the challenges facing pharmaceutical sales and marketing managers in today's environment. The event - "Innovation in Today's Pharmaceutical Environment" - will feature a series of presentations given by inVentiv Health management as well as guest speakers from the pharmaceutical industry including Roger Longman, Managing Partner of Windhover Information, Inc. and editor of In Vivo magazine. The half-day conference is part of the inVentiv Pharma Forum conference series.

The conference will take place on Thursday, June 21, 2007 at the Grand Summit Hotel located at 570 Springfield Avenue, Summit, New Jersey. Registration and breakfast will begin at 8:30 a.m. Lunch will be served at 12:15 p.m. during a panel discussion. The event is scheduled to end by 2:00 p.m.

Hosted by Terry Herring, President and CEO of inVentiv Commercial and COO of inVentiv Health, conference presentations will cover competitive pressures driving change in the sales and marketing area, strategies for customizing the new field force, opportunities for creating deeper connections with customers and the outlook for the industry including prevalent trends in the current environment. In addition to Mr. Longman, speakers include Phil Deschamps, President and CEO, GSW Worldwide and Paul Mignon, President and COO, Ventiv Pharma Teams.


Mr. Longman will also moderate a panel discussion over lunch involving the aforementioned speakers as well as Jaye L. Thompson, PhD - Senior VP, inVentiv Clinical Solutions, and Denice Torres - VP, Marketing - Ortho-McNeil Neurologics.

Commenting on the relevance of the event in today's marketplace, Terry Herring, said, "Market dynamics and innovation to keep up with the changes taking place is something we discuss quite often with our clients. As a result, we thought we would design an open forum in which sales and marketing professionals can discuss the challenges of the changing industry environment and we can share insights on new sales and marketing models for overcoming these challenges. We welcome all of our clients and representatives from the pharmaceutical industry to join us in what will certainly be a highly engaging discussion."

For more information about the inVentiv Pharma Forum event or to sign up for the event, please email inVentivforum@inventivhealth.com.

About inVentiv Health

inVentiv Health is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its three core business segments: inVentiv Clinical, inVentiv Communications and inVentiv Commercial. inVentiv Health currently works with over 200 unique pharmaceutical, biotech and life sciences clients, including all top 20 global pharmaceutical companies. For more information, visit http://www.inventivhealth.com/.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
© 2007 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.